Further, Wright et al. studied the expression of SGLT2 in pancreatic cancers, prostate cancers, and glioblastomas and highlighted that Me4FDG could act as a new radiotracer to detect SGLT activity, unlike 2FDG, which acts as a substrate for GLUT1 in FDG-PET scans [24]. Here, SLC5A2 is linked to prostate carcinoma.